厄贝沙坦氢氯噻嗪片对原发性高血压患者肿瘤坏死因子α和白细胞介素6水平的影响

Irbesartan Hydrochlorothiazide Tablets Influence on the Level of Tumor Necrosis Factor-α and Interleukin-6 of Patients with Essential Hypertension

目的检测原发性高血压病患者治疗前后血清肿瘤坏死因子α(TNF-α)和白细胞介素(IL)-6的变化,并探讨其在高血压发病过程中的机制。方法原发性高血压患者72例,随机分为治疗组和对照组,每组36例。对照组给予非洛地平缓释片,治疗组给予厄贝沙坦氢氯噻嗪片,两组均服药12周。两组于治疗前和治疗后12周分别测量血压和用酶联免疫吸附法(ELISA法)检测TNF-α和IL-6水平并进行比较分析。结果治疗12周后两组血压均明显下降(P<0.01),但治疗组收缩压下降更为明显(P<0.01)。治疗组治疗后与治疗前比较TNF-α和IL-6水平均明显下降(P<0.01),而对照组治疗后与治疗前比较TNF-α和IL-6水平下降不明显(P>0.05);治疗后治疗组与对照组比较TNF-α和IL-6水平均有显著性差异(P<0.01)。结论用厄贝沙坦氢氯噻嗪片治疗原发性高血压患者可引起TNF-α和IL-6水平显著下降,这对判断患者病情进展程度,评价预后可能有重要临床价值。

Objective To study effects of serum cytokines tumor necrosis factor-α（TNF-α）and interleukin（IL-6） for patients with essential hypertension before and after treatment,and explore its mechanism in pathogenesis of hypertension.Methods 72 patients with essential hypertension were randomly divided into treatment group and control group（n=36）.Control group received felodipine extended-release tablets,the treatment group was given irbesartan hydrochlorothiazide tablets,and the two groups were taking 12 weeks.Before treatment and 12 weeks after treatment,blood pressure were measured and levels of TNF-α and IL-6 were detected by enzyme-linked immunosorbent assay（ELISA）,and comparative analysis was done.Results After 12 weeks of treatment,two groups were significantly reduced for blood pressure（P〈0.01）,but the treatment group decreased systolic blood pressure is more significant（P〈0.01）.After treatment compared with before treatment TNF-α and IL-6 levels were significantly decreased（P〈0.01）in treatment group,while the control group after treatment compared with before treatment,TNF-α and IL-6 levels were not decreased（P〉0.05）.Treatment group compared with the control group,TNF-α and IL-6 levels were significantly different（P〈0.01）.Conclusion Irbesartan hydrochlorothiazide tablets in the treatment of primary hypertension can lead to TNF-α and IL-6 levels decrease significantly,which determine the extent of disease progression in patients to evaluate the prognosis with important clinical value.